Literature DB >> 3559930

Liquid chromatographic assay and disposition of carvedilol in healthy volunteers.

F Varin, L X Cubeddu, J R Powell.   

Abstract

Quantitative determination of serum concentrations of carvedilol [(+/-)-1-(carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl) amino]-2-propanol], a combined alpha- and beta-adrenergic receptor antagonist, was obtained using HPLC with spectrofluorometric detection. Carvedilol was extracted from alkalinized serum with ether and was subsequently back extracted with diluted phosphoric acid. This method proved to be sensitive and reproducible (mean coefficient of variation of 6.1% for 0.25 to 150 nanograms per milliliter of serum). A single dose of carvedilol (5, 10, or 15 mg) was given as an intravenous infusion to three healthy volunteers. Carvedilol serum concentration-time profiles were fitted best to a three-compartment model and the pharmacokinetic data revealed the following mean values: Vdss of 1.97 L/kg, mean residence time (MRT) of 4.66 h, and CL of 0.437 L X h-1 X kg-1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3559930     DOI: 10.1002/jps.2600751218

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.

Authors:  J J McPhillips; G T Schwemer; D I Scott; M Zinny; D Patterson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

Review 3.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  In Vitro Permeation Studies on Carvedilol Containing Dissolving Microarray Patches Quantified Using a Rapid and Simple HPLC-UV Analytical Method.

Authors:  Qonita Kurnia Anjani; Akmal Hidayat Bin Sabri; Mary B McGuckin; Huanhuan Li; Khuriah Abdul Hamid; Ryan F Donnelly
Journal:  AAPS PharmSciTech       Date:  2022-10-04       Impact factor: 4.026

5.  A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose.

Authors:  Wanna Eiamart; Nantaporn Prompila; Yaowatree Jumroen; Nonlanee Sayankuldilok; Pajaree Chariyavilaskul; Supeecha Wittayalertpanya
Journal:  Res Pharm Sci       Date:  2022-04-18

Review 6.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Influence of vitamin C on the absorption and first pass metabolism of propranolol.

Authors:  J P Gonzalez; A Valdivieso; R Calvo; J M Rodríguez-Sasiaín; R Jimenez; C Aguirre; P du Souich
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

9.  Sensitive assay for carvedilol in tablets and spiked human plasma using a flow-injection chemiluminometric method.

Authors:  Nawal Al Arfaj; Heba H Abdine; Maha A Sultan
Journal:  Int J Biomed Sci       Date:  2007-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.